Recent News

• 11.09.2025 - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
• 08.31.2025 - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
• 08.31.2025 - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
• 08.31.2025 - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
• 08.30.2025 - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
• 08.30.2025 - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
• 08.30.2025 - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
• 08.25.2025 - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
• 08.25.2025 - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
• 07.30.2025 - Amarin Corporation’s Second Quarter 2025 Results

Recent Filings

• 10.31.2025 - 3 Initial statement of beneficial ownership of securities
• 10.29.2025 - 8-K Current report
• 10.29.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2025 - EX-99.1 EX-99.1
• 10.22.2025 - 8-K Current report
• 08.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.31.2025 - EFFECT Notice of Effectiveness